Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms

British Journal of Cancer

Volumn 116, Issue 3, 2017, Pages 335-343

  Romano, Michela ^a   Della Porta, Matteo Giovanni ^b,c   Gallì, Anna ^b   Panini, Nicolò ^a   Licandro, Simonetta Andrea ^a   Bello, Ezia ^a   Craparotta, Ilaria ^a   Rosti, Vittorio ^b   Bonetti, Elisa ^b   Tancredi, Richard ^d   Rossi, Marianna ^b   Mannarino, Laura ^a   Marchini, Sergio ^a   Porcu, Luca ^a   Galmarini, Carlos M ^e   Zambelli, Alberto ^f   Zecca, Marco ^b   Locatelli, Franco ^c,g   Cazzola, Mario ^b,c   Biondi, Andrea ^h   Rambaldi, Alessandro ^f   Allavena, Paola ⁱ   Erba, Eugenio ^a   D'Incalci, Maurizio ^a   more..

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d IRCCS   (Italy)

^e PHARMAMAR S A   (Spain)

^f PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^g BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

ⁱ HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

apoptosis; CMML; cytotoxicity; gene expression; JMML; Rho GTPases; trabectedin

Indexed keywords

AZACITIDINE; BONE MORPHOGENETIC PROTEIN 4; CD14 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12P35; INTERLEUKIN 12P40; MAMMALIAN TARGET OF RAPAMYCIN; MICROSOMAL AMINOPEPTIDASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; RHO GTPASE ARHGAP10; RHO GTPASE ARHGAP26; RHO GTPASE SRGAP2; RHO GTPASE VAV 3; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; STAT5A PROTEIN; TRABECTEDIN; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR SP1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; 1,3 DIOXOLANE DERIVATIVE; ALKYLATING AGENT; TETRAHYDROISOQUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PATIENT; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; COLONY FORMING UNIT GM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; FEMALE; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKEMIA CELL LINE; MIXED MYELODYSPLASTIC MYELOPROLIFERATIVE DISEASE; MONOCYTE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; ANIMAL; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETICS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; MYELODYSPLASTIC SYNDROMES; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; TUMOR STEM CELL ASSAY;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; CELL PROLIFERATION; DIOXOLES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; MICE; MICE, NUDE; MYELODYSPLASTIC SYNDROMES; TETRAHYDROISOQUINOLINES; TUMOR STEM CELL ASSAY;

EID: 85009231048     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.424     Document Type: Article

References (51)

1. Allavena P, Mantovani A (2012) Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol 167: 195-205.
2. Allavena P, Signorelli M, Chieppa M, Erba E, Bianchi G, Marchesi F, Olimpio CO, Bonardi C, Garbi A, Lissoni A, de Braud F, Jimeno J, D'Incalci M (2005) Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res 65: 2964-2971.
3. Bourne HR, Sanders DA, McCormick F (1991) The GTPase superfamily: conserved structure and molecular mechanism. Nature 349: 117-127.
4. Calura E, Fruscio R, Paracchini L, Bignotti E, Ravaggi A, Martini P, Sales G, Beltrame L, Clivio L, Ceppi L, Di Marino M, Fuso Nerini I, Zanotti L, Cavalieri D, Cattoretti G, Perego P, Milani R, Katsaros D, Tognon G, Sartori E, Pecorelli S, Mangioni C, D'Incalci M, Romualdi C, Marchini S (2013) MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities. Clin Cancer Res 19: 4114-4123.
5. Cazzola M, Della Porta MG, Malcovati L (2013) The genetic basis of myelodysplasia and its clinical relevance. Blood 122: 4021-4034.
6. Ceriani L, Ferrari M, Zangarini M, Licandro SA, Bello E, Frapolli R, Falcetta F, D'Incalci M, Libener R, Grosso F, Aviles P, Zucchetti M (2015) HPLC-MS/MS method to measure trabectedin in tumors: preliminary PK study in a mesothelioma xenograft model. Bioanalysis 7: 1831-1842.
7. D'Incalci M, Galmarini CM (2010) A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 9: 2157-2163.
8. D'Incalci M, Badri N, Galmarini CM, Allavena P (2014) Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. Br J Cancer 111: 646-650.
9. Damia G, Silvestri S, Carrassa L, Filiberti L, Faircloth GT, Liberi G, Foiani M, D'Incalci M (2001) Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 92: 583-588.
10. de Vries AC, Zwaan CM, van den Heuvel-Eibrink MM (2010) Molecular basis of juvenile myelomonocytic leukemia. Haematologica 95: 179-182.
11. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gomez J, Park YC, Le Cesne A (2009) Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 27: 4188-4196.
12. Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR (2016) Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol 34: 786-793.
13. DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, Coussens LM (2009) CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16: 91-102.
14. Di Giandomenico S, Frapolli R, Bello E, Uboldi S, Licandro SA, Marchini S, Beltrame L, Brich S, Mauro V, Tamborini E, Pilotti S, Casali PG, Grosso F, Sanfilippo R, Gronchi A, Mantovani R, Gatta R, Galmarini CM, Sousa-Faro JM, D'Incalci M (2014) Mode of action of trabectedin in myxoid liposarcomas. Oncogene 33: 5201-5210.
15. Drexler HG, Quentmeier H, MacLeod RA (2004) Malignant hematopoietic cell lines: in vitro models for the study of MLL gene alterations. Leukemia 18: 227-232.
16. Emanuel PD (2008) Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Leukemia 22: 1335-1342.
17. Erba E, Bergamaschi D, Bassano L, Damia G, Ronzoni S, Faircloth GT, D'Incalci M (2001) Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 37: 97-105.
18. Etienne-Manneville S, Hall A (2002) Rho GTPases in cell biology. Nature 420: 629-635.
19. Friedman D, Hu Z, Kolb EA, Gorfajn B, Scotto KW (2002) Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res 62: 3377-3381.
20. Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, Nebuloni M, van Rooijen N, Mortarini R, Beltrame L, Marchini S, Fuso Nerini I, Sanfilippo R, Casali PG, Pilotti S, Galmarini CM, Anichini A, Mantovani A, D'Incalci M, Allavena P (2013) Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 23: 249-262.
21. Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R, Casali PG, Gronchi A, Virdis E, Tarantino E, Pilotti S, Greco A, Nebuloni M, Galmarini CM, Tercero JC, Mantovani A, D'Incalci M, Allavena P (2010) Antitumor and antiinflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res 70: 2235-2244.
22. Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A, Sanfilippo R, Casieri P, Collini P, Dileo P, Spreafico C, Stacchiotti S, Tamborini E, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Fletcher JA, Pilotti S, Casali PG (2007) Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 8: 595-602.
23. Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M, Berthon C, Ades L, Fenaux P, Beyne-Rauzy O, Vey N, Braun T, Haferlach T, Dreyfus F, Cross NC, Preudhomme C, Bernard OA, Fontenay M, Vainchenker W, Schnittger S, Birnbaum D, Droin N, Solary E (2013) Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 31: 2428-2436.
24. Itzykson R, Solary E (2013) An evolutionary perspective on chronic myelomonocytic leukemia. Leukemia 27: 1441-1450.
25. Kourlas PJ, Strout MP, Becknell B, Veronese ML, Croce CM, Theil KS, Krahe R, Ruutu T, Knuutila S, Bloomfield CD, Caligiuri MA (2000) Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: evidence for its fusion with MLL in acute myeloid leukemia. Proc Natl Acad Sci USA 97: 2145-2150.
26. Lange B, Valtieri M, Santoli D, Caracciolo D, Mavilio F, Gemperlein I, Griffin C, Emanuel B, Finan J, Nowell P (1987) Growth factor requirements of childhood acute leukemia: establishment of GM-CSFdependent cell lines. Blood 70: 192-199.
27. Liguori M, Buracchi C, Pasqualini F, Bergomas F, Pesce S, Sironi M, Grizzi F, Mantovani A, Belgiovine C, Allavena P (2016) Functional TRAIL receptors in monocytes and tumor-associated macrophages: a possible targeting pathway in the tumor microenvironment. Oncotarget 7: 41662-41676.
28. Locatelli F, Niemeyer CM (2015) How I treat juvenile myelomonocytic leukemia. Blood 125: 1083-1090.
29. Locatelli F, Nollke P, Zecca M, Korthof E, Lanino E, Peters C, Pession A, Kabisch H, Uderzo C, Bonfim CS, Bader P, Dilloo D, Stary J, Fischer A, Revesz T, Fuhrer M, Hasle H, Trebo M, van den Heuvel-Eibrink MM, Fenu S, Strahm B, Giorgiani G, Bonora MR, Duffner U, Niemeyer CM (2005) Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood 105: 410-419.
30. Loh ML (2010) Childhood myelodysplastic syndrome: focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemia. Hematol Am Soc Hematol Educ Program 2010: 357-362.
31. Loh ML (2011) Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia. Br J Haematol 152: 677-687.
32. Minuzzo M, Marchini S, Broggini M, Faircloth G, D'Incalci M, Mantovani R (2000) Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci USA 97: 6780-6784.
33. Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson AN, Rolski J, Gorbounova VA, Ghatage P, Bidzinski M, Shen K, Ngan HY, Vergote IB, Nam JH, Park YC, Lebedinsky CA, Poveda AM (2010) Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol 28: 3107-3114.
34. Mulloy JC, Cancelas JA, Filippi MD, Kalfa TA, Guo F, Zheng Y (2010) Rho GTPases in hematopoiesis and hemopathies. Blood 115: 936-947.
35. Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, McDaniel JM, Kim E, Bebbington C, Baer M, Yarranton G, Lancet J, Komrokji RS, Abdel-Wahab O, List AF, Epling-Burnette PK (2013) GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood 121: 5068-5077.
36. Patnaik MM, Parikh SA, Hanson CA, Tefferi A (2014) Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review. Br J Haematol 165: 273-286.
37. Patnaik MM, Tefferi A (2016) Chronic myelomonocytic leukemia: focus on clinical practice. Mayo Clin Proc 91: 259-272.
38. Perez-Ruixo JJ, Zannikos P, Hirankarn S, Stuyckens K, Ludwig EA, Soto-Matos A, Lopez-Lazaro L, Owen JS (2007) Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients. Clin Pharmacokinet 46: 867-884.
39. Rucker FG, Sander S, Dohner K, Dohner H, Pollack JR, Bullinger L (2006) Molecular profiling reveals myeloid leukemia cell lines to be faithful model systems characterized by distinct genomic aberrations. Leukemia 20: 994-1001.
40. Sessa C, Cresta S, Noberasco C, Capri G, Gallerani E, De Braud F, Zucchetti M, D'Incalci M, Locatelli A, Marsoni S, Corradino I, Minoia C, Zintl P, Gianni L (2009a) Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours. Eur J Cancer 45: 2116-2122.
41. Sessa C, Perotti A, Noberasco C, De Braud F, Gallerani E, Cresta S, Zucchetti M, Vigano L, Locatelli A, Jimeno J, Feilchenfeldt JW, D'Incalci M, Capri G, Ielmini N, Gianni L (2009b) Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. Eur J Cancer 45: 1153-1161.
42. Soares DG, Poletto NP, Bonatto D, Salvador M, Schwartsmann G, Henriques JA (2005) Low cytotoxicity of ecteinascidin 743 in yeast lacking the major endonucleolytic enzymes of base and nucleotide excision repair pathways. Biochem Pharmacol 70: 59-69.
43. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD (2010) Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 362: 875-885.
44. Stieglitz E, Taylor-Weiner AN, Chang TY, Gelston LC, Wang YD, Mazor T, Esquivel E, Yu A, Seepo S, Olsen SR, Rosenberg M, Archambeault SL, Abusin G, Beckman K, Brown PA, Briones M, Carcamo B, Cooper T, Dahl GV, Emanuel PD, Fluchel MN, Goyal RK, Hayashi RJ, Hitzler J, Hugge C, Liu YL, Messinger YH, Mahoney Jr. DH, Monteleone P, Nemecek ER, Roehrs PA, Schore RJ, Stine KC, Takemoto CM, Toretsky JA, Costello JF, Olshen AB, Stewart C, Li Y, Ma J, Gerbing RB, Alonzo TA, Getz G, Gruber TA, Golub TR, Stegmaier K, Loh ML (2015) The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet 47: 1326-1333.
45. Symeonidis A, van Biezen A, de Wreede L, Piciocchi A, Finke J, Beelen D, Bornhauser M, Cornelissen J, Volin L, Mufti G, Chalandon Y, Ganser A, Bruno B, Niederwieser D, Kobbe G, Schwerdtfeger R, de Witte T, Robin M, Kroger N (2015) Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol 171: 239-246.
46. Tavecchio M, Natoli C, Ubezio P, Erba E, D'Incalci M (2007) Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach. Cell Prolif 40: 885-904.
47. Tavecchio M, Simone M, Erba E, Chiolo I, Liberi G, Foiani M, D'Incalci M, Damia G (2008) Role of homologous recombination in trabectedininduced DNA damage. Eur J Cancer 44: 609-618.
48. Troeger A, Williams DA (2013) Hematopoietic-specific Rho GTPases Rac2 and RhoH and human blood disorders. Exp Cell Res 319: 2375-2383.
49. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114: 937-951.
50. Yovine A, Riofrio M, Blay JY, Brain E, Alexandre J, Kahatt C, Taamma A, Jimeno J, Martin C, Salhi Y, Cvitkovic E, Misset JL (2004) Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 22: 890-899.
51. Zewail-Foote M, Hurley LH (1999) Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem 42: 2493-2497.